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Soy beans contain isoflavones, including daidzein and genistein, with biological
activities related to therapeutic effects in reducing osteoporosis, decreasing adverse
menopausal manifestations, providing protection from cardiovascular diseases, and
reducing hormone-dependent cancers and age-related cognitive-decline. Daidzein has
been described as inhibiting the aldehyde-dehydrogenase-2 enzyme (ALDH2), and
reducing alcohol use in clinical pilot studies. Our aim was to evaluate the possible
interactions between a soy extract product and alcohol in a crossover, single blind,
randomized study. Ten healthy male volunteers participated in two experimental
sessions: one with a single dose of alcohol (0.5 g/kg, Vodka Absolut, Sweden), and the
other with four capsules of a soy extract product (Super-Absorbable Soy Isoflavones,
Life-Extension, United States) and, 2 h later, the same dose of alcohol. Results
showed no differences in vital signs except a slightly higher significative reduction in
diastolic blood pressure at 2, 3, 4, and 8 h after administration with alcohol alone in
comparison with soy extract+alcohol. Ethanol-induced subjective and adverse effects
were similar for both conditions with the exception of headache (higher at 8 h after
alcohol alone). Our results demonstrate that a single dose of a soy isoflavone extract did
not influence alcohol pharmacokinetics and pharmacological effects and did not induce
any disulfiram-reaction symptoms. Soy extract and alcohol did not interact and can be
administered safely.
Keywords: soy extracts, isoflavones, daidzein, genistein, aldehyde-dehydrogenase-2 enzyme, alcohol,
clinical trial
INTRODUCTION
Isoflavones are biologically active polyphenols found in soybeans and other legumes. In the
former, the principal ones are daidzin (40%) and genistin (50%) which transform into two active
compounds, daidzein and genistein, respectively (U.S. Department of Agriculture, Agricultural
Research Service, 2015). Daidzein is also metabolized by intestinal bacteria to the active
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compound equol. Daidzein consumption has been related
to phytoestrogen and antioxidant activity, a lower incidence
of menopausal symptoms (Messina, 2014), and a reduction
in osteoporosis, breast cancer, and cardiovascular diseases
(Michelfelder, 2009). This isoflavone is more selective for
estrogen receptor (ER)/beta than estradiol which could
explain such activities. The ingestion of soy isoflavones
is considered safe, the most common adverse effects are
gastrointestinal (diarrhea) and more rarely headache,
prolonged menstrual period, amenorrhea, dizziness, and
musculoskeletal complaints (Michelfelder, 2009). Some
isoflavones, especially daidzin-daidzein, have been reported
to inhibit the aldehyde-dehydrogenase-2 enzyme (ALDH2) (Gao
et al., 2001; Lowe et al., 2008; Koppaka et al., 2012).
Kudzu (Pueraria lobata) root extracts and flowers contain
isoflavones, for instance, puerarin (about 60% of the total
isoflavones), and daidzin. Kudzu is used in traditional
Japanese and Chinese medicine to treat alcohol hangover
and alcohol substance use disorder (Overstreet et al., 2003a,b).
Some studies in animal models have shown that daidzin
and synthetic analogs have the capacity to reduce alcohol
intake (Overstreet et al., 1996; Gao et al., 2003; Arolfo
et al., 2009). In humans, a pilot study in a naturalistic
setting demonstrated that the administration of a kudzu
extract reduced alcohol consumption in heavy drinkers
(Lukas et al., 2005). In controlled clinical trials with healthy
volunteers, a reduction in alcohol intake when kudzu
extract isoflavones were taken before drinking was reported
(Penetar et al., 2012; Lukas et al., 2013; Penetar et al., 2015).
As already established, alcohol is biotransformed
enzymatically to acetaldehyde by alcohol-dehydrogenase (ADH)
and later metabolized into acetate by aldehyde-dehydrogenase
(ALDH1). Disulfiram, used for the treatment of alcohol
substance use, inhibits ALDH1 and ALDH2 irreversibly,
producing an accumulation of acetaldehyde concentrations
in blood which leads to undesirable effects if alcohol
is simultaneously consumed. Symptoms, which include
sickness, nausea, vomit, sweating, dizziness, and facial
erythema, are known as the “disulfiram-reaction”
or “antabuse-reaction.”
For centuries traditional Chinese medicine has employed
different isoflavones for the treatment of alcohol substance use
(Keung, 2003; Lu et al., 2009; Soyka and Rösner, 2010) with
the advantage that they do not affect acetaldehyde levels, induce
disulfiram-like effects (Penetar et al., 2011), or alter the sleep cycle
(Bracken et al., 2011).
There are no previously published papers evaluating the
possible interference/influence of soy isoflavone extracts on
alcohol pharmacokinetics, acute pharmacological effects, and
induction of a “disulfiram-like effect” despite their potential
interaction in the treatment of alcohol abuse. The aim of
the present study was to evaluate the interactions between
a soy extract containing isoflavones and alcohol, in relation
to the pharmacokinetics and acute effects of alcohol, in
order to design future clinical trials to assess the possible




The study protocol was approved by the local Human Research
Ethics Committee (CEIC-Parc de Salut Mar) and conducted in
accordance with the Helsinki Declaration and local legislation.
The trial was registered in a public database (ClinicalTrials.gov
Identifier: NCT02309801). All the participants were informed
about the study and signed a written informed consent
before participation. All subjects were financially compensated
for their participation.
The study was a randomized, single-blinded (the participants
were informed that they could receive different doses of alcohol
in the two sessions), and crossover clinical trial. Subjects
participated in two different experimental sessions separated by
at least 3 days. In one session they received a glass of water
(240 mL) and 2 h later a single oral dose of alcohol was
administered (0.5 g/kg, Vodka Absolut R© 40◦, Sweden); in the
other, they were given four capsules containing a soy extract
product with a glass of water (240 mL) and 2 h later the
same dose of alcohol.
Soy Isoflavone Extract
A commercial soy extract product (Super-Absorbable
Soy Isoflavones R©, hard gelatin capsules, Life-Extension,
United States) was employed. According to the manufacturer
each capsule contained 54 mg of total isoflavones (22 mg
daidzin-daidzein, 28 mg genistin-genistein, and 4 mg
glycitin-glycitein). The dose administered (four capsules) was
chosen in order to provide a total content of daidzin/daidzein
(approximately 88 mg) which represented twice the dose
recommended for the symptomatic therapy of menopausal
symptoms (Brewer, 1984; Christensen et al., 1991; Gao et al.,
2001) or that used in trials for asthma therapy (Smith et al., 2015).
Subjects
A total of 10 healthy males were recruited from a volunteer
database. The screening visit took place within the 3 weeks prior
to commencing the study sessions. Subjects underwent a general
physical examination, a 12-lead ECG, and a complete blood
and urine analysis, including drugs of abuse in urine. Inclusion
criteria were (i) recreational use of alcohol (<4 units of alcohol
per day); (ii) previous experience of acute alcohol intoxication;
and (iii) no history of substance abuse/dependence according
to the Diagnosis and Statistical Criteria for Mental Disorders
(DSM-IV-R). Exclusion criteria were (i) current tobacco smokers;
(ii) current or previous history of mental disorders; (iii) any
somatic illness that could interfere with alcohol and soy; (iv)
the consumption of >5/day drinks of tea, coffee or similar
xanthine-containing beverages during the 3 months prior to
the study; and (v) the use of soy derivatives during the
previous month.
Procedure
Subjects were admitted to the Clinical Research Unit facilities
at 07:45 a.m. after an overnight fast. Upon arrival, they
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were asked about any drug consumption or adverse event
that could affect their participation. They were requested to
refrain from using any psychoactive drug for a minimum
of 7 days prior to the study and throughout it, and
from consuming caffeinated products for 24 h and alcohol
for 48 h. They were also asked to follow a diet free
from daidzein (soy and derivatives) 3 days before and
48 h after each session. A urine sample was collected
for drug of abuse testing (Instant-View R©, Multipanel 10
Test Drug Screen, Alfa Scientific Designs Inc., Poway, CA,
United States). Alcohol concentrations in breath were analyzed.
An intravenous catheter in the non-dominant arm was inserted
for blood sampling.
Physiological and Subjective Effects
Non-invasive systolic blood pressure (SBP), diastolic blood
pressure (DBP), heart rate (HR), oral and cutaneous
facial temperature (OT, FT) were repeatedly recorded at
baseline, immediately before capsule administration, and at 2
(immediately before beverage administration), 2.5, 3, 4, 5, 6, 8,
and 10 h after first administration. All assessments were carried
out with a DinamapTM 8100-T vital signs monitor (Critikon,
TABLE 1 | Summary of results of the physiological and subjective effects observed after administration of soy extract+alcohol and alcohol (n = 10).
Variable Parameter Soy extract+Alcohol Alcohol P-value
Physiological
SBP Emax −4.5 ± 11.66 −9.2 ± 11.05 0.323
AUC0−10 −24.4 ± 40.4 −39.17 ± 41.7 0.302
DBP Emax −4.8 ± 9.92 −10.5 ± 8.72 0.081
AUC0−10 −25.8 ± 41.36 −58.8 ± 35.59 0.052
HR Emax −3.7 ± 13.09 −1.2 ± 15.26 0.368
AUC0−10 −14.9 ± 61.2 −9.75 ± 59.58 0.759
OT Emax −0.26 ± 0.31 −0.23 ± 0.47 0.873
AUC0−10 −0.967 ± 1.159 −1.2 ± 2.19 0.747
FT Emax 0.75 ± 1.34 1.59 ± 0.67 0.039
AUC0−10 6.04 ± 7.2 8.1 ± 5.59 0.205
Visual Analog Scales
Drunkenness Emax 17.6 ± 29.018 20.8 ± 19.1 0.602
AUC0−10 35.36 ± 84.037 25.387 ± 35.1 0.569
Content Emax 18.1 ± 30.2 23.9 ± 26.2 0.361
AUC0−10 29.687 ± 67.9 29.91 ± 47.07 0.980
Nausea Emax 0.5 ± 1.58 0.8 ± 1.75 0.718
AUC0−10 0.2 ± 0.79 1.1 ± 3.1 0.416
Vertigo Emax 3.2 ± 10.119 2.2 ± 6.9 0.812
AUC0−10 5.27 ± 16.68 0.9 ± 3 0.449
Dizziness Emax 9.4 ± 22.667 10.9 ± 18.3 0.687
AUC0−10 19.9 ± 55.3 22.7 ± 47.09 0.627
Face flushing Emax 7.5 ± 13.938 9.6 ± 14.9 0.696
AUC0−10 16.3 ± 37.38 10.98 ± 20.8 0.614
Headache Emax 5.3 ± 9.58 16.2 ± 27.9 0.217
AUC0−10 18.16 ± 40.4 48.3 ± 87.9 0.274
Breathing difficulty Emax 0 0 −
AUC0−10 0 0 −
ARCI questionnaire
ARCI-PCAG Emax 2.4 ± 3.6 3.4 ± 3.59 0.266
AUC0−10 9.8 ± 14.56 14.05 ± 14.2 0.237
ARCI-MBG Emax 2.6 ± 2.836 2.7 ± 3.3 0.876
AUC0−10 4.48 ± 5.01 3.4 ± 3.2 0.329
ARCI-LSD Emax 4.8 ± 1.47 5.2 ± 1.7 0.373
AUC0−10 42.26 ± 7.1 43.2 ± 8.27 0.328
ARCI-LSD Emax 4.5 ± 0.97 4.6 ± 1.07 0.882
AUC0−10 38.26 ± 5.8 36.7 ± 5.5 0.355
ARCI-BG ARCI-A Emax 1.4 ± 1.4 1.8 ± 1.686 0.168
AUC0−10 3.07 ± 3.8 4.5 ± 4.47 0.113
Values are differences from baseline (mean values and standard deviation). Systolic blood pressure (SBP, mmHg); diastolic blood pressure (DBP, mmHg), heart rate
(HR, beats/min), (temperature (T, ◦C), visual analog scale (VAS, mm), Addiction Research Center Inventory questionnaire (ARCI, score), Emax = maximal/peak effects,
AUC0−10, area under the curve from 0 to 10 h.
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Tampa, FL, United States). Cutaneous facial temperature was
measured at the same time with an additional monitor (Critikon,
Tampa, FL, United States).
Subjective effects were evaluated using a set of visual analog
scales (VAS) at baseline (0 h), 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8,
and 10 h after first administration. VAS (100 mm) were labeled
with different adjectives marked at opposite ends from “not at all”
to “extremely” (Peiró et al., 2013; Farré et al., 2015; Papaseit et al.,
2016). Subjects were asked to rate effects of drunkenness, content,
nausea, vertigo, dizziness, feeling of face flushing, headache, and
breathing difficulty.
In addition, the 49-item short form Addiction Research
Center Inventory (ARCI) was administered at baseline and at
2, 2.75, 3.5, and 10 h after first treatment administration. The
Spanish validated version of the ARCI (Lamas et al., 1994) is
sensitive to the effects of a variety of drug of abuse classes with five
subscales: PCAG (pentobarbital-chlorpromazine-alcohol group,
a measure of sedation); MBG (morphine-benzedrine group, a
measure of euphoria); LSD (lysergic acid diethylamide group, a
measure of dysphoria and somatic symptoms); BG (benzedrine
group, a stimulant subscale relating to intellectual efficiency and
energy); and A (amphetamine, a measure of d-amphetamine
effects) (Farré et al., 2015).
Pharmacokinetics
Blood samples and ethanol breath concentrations were collected
at baseline (before soy extract administration), and at 2 (before
ethanol administration), 2.25, 2.5, 2.75, 3, 4, 5, 6, 7, 8, 10, and
24 h after soy extract administration. Ethanol was determined
in blood (DRI R© Ethyl Alcohol Assay, Thermo Fisher, Fremont,
CA, United States) and breath (Alcotest, Dräger, Germany).
Daidzein, genistein, and the endogenous metabolite equol
were determined by liquid chromatography coupled to tandem
mass spectrometry (LC/MS/MS) using a validated method
(Rodríguez-Morató et al., 2015).
Statistical Analysis
Effects
Differences with respect to baseline were calculated for vital signs
(SBP, DBP, HR, and OT-FT) and subjective effects (VAS, ARCI).
Maximum/peak effects (Emax) and the time to reach maximum
effects (tmax) were also determined for the previously mentioned
variables. The area under the curve of the concentrations from 0
to 10 h (AUC0−10 h) using the trapezoidal rule was calculated for
vital signs and subjective effects.
For the statistical comparison of AUC and Emax a
Student’s t-test for paired samples was employed. For tmax a
non-parametric Wilcoxon test was used. A repeated measure
ANOVA with two factors (treatment and time) was used to
compare the time course of effects. When treatment or the
treatment× time interaction was statistically significant, multiple
Tukey post hoc comparisons were performed at each time point.
Experimental Pharmacokinetic Parameters
Peak concentration (Cmax), time to reach peak concentrations
(Tmax), and area under the concentration-time curve from 0 to
FIGURE 1 | Time course of the physiological and subjective effects after administration of alcohol and soy extract+alcohol. Mean values and standard error (n = 10).
Figures correspond to systolic and diastolic blood pressure (mmHg), heart rate (beats/min), and drunkenness (mm).
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FIGURE 2 | Plasma concentrations of ethanol after the administration of
alcohol and soy extract + alcohol. Mean values and standard error (n = 10).
TABLE 2 | Pharmacokinetic parameters of alcohol in plasma (n = 10).
Pharmacokinetic
parameters
Soy extract + Alcohol Alcohol P-value
Mean ± SD Mean ± SD
Cmax (ng/ml) 77 ± 16.99 77 ± 22.25 1
AUC0−10 (ng/ml/h) 216.57 ± 30.40 219.67 ± 27.2 0.806
Tmax (h)∗ 2.75 (2.5-4) 3 (2.5-4) 0.256
Mean values and standard deviation) (mean values and standard deviation) for
Cmax and AUC. Median values and range for Tmax. AUC, area under the curve;
Cmax, peak/maximal concentration; SD, standard deviation; Tmax, time to reach
peak concentrations. ∗Median values and range for Tmax (Wilcoxon test).
10 h (AUC0−10) from ethanol plasma concentrations over time
were determined using Pharmacokinetic Functions for Microsoft
Excel (Joel Usansky, Atul Desai, and Diane Tang-Liu, Department
of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA,
United States).
All statistical tests were performed with the PASW Statistics




The 10 healthy male participants had a mean age of
25.2 ± 3.6 years, mean weight 74.0 ± 7.0 kg, and a body mass
index of 23.3± 2.6. The participants consumed ethanol regularly
(10.0 ± 7.1 standard drinks/week; 1 standard drink = 10 g of
pure ethanol). All subjects completed the study. None required
special therapy or care throughout the study and no serious
adverse events occurred during the experimental sessions.
Physiological Effects
Table 1 shows a summary of the physiological and subjective
effects. Regarding vital signs, no differences were observed in
Emax and AUC for SBP, DBP, HR, and oral temperature between
both conditions: alcohol and soy extract+alcohol (Figure 1, SBP,
FIGURE 3 | Plasma concentrations of daidzein and genistein after the
administration of the soy extract. Mean values and standard error (n = 10).
DBP HR). A slight difference in cutaneous facial temperature
was found in the Emax (1.59 and 0.75◦C after alcohol and
soy extract+alcohol, respectively). In the time course analysis, a
slightly higher reduction of DBP was reported at 2 h (−2.89, 0.8;
p < 0.05), 3 h (−4.5,−0.3; p < 0.05), 4 h (−9.67,−3.3; p < 0.01),
and 8 h (−4.78, −1; p < 0.05) after administration with alcohol
alone in comparison with soy extract+alcohol, respectively.
Subjective Effects
In VAS, alcohol and soy extract+alcohol showed very similar
subjective effects (drunkenness, content, nausea, vertigo,
dizziness, face flushing, and breathing difficulty), without
statistically significant differences (Figure 1, drunkenness).
However, the alcohol alone condition, in contrast to the soy
extract+alcohol, showed higher scores for headache at 8 h
(16 mm, 3.7 mm, respectively, p < 0.01).
With regard to the ARCI questionnaire, no differences were
reported between alcohol and soy extract+alcohol.
Alcohol Concentrations
Pharmacokinetic parameters for blood ethanol concentrations
over time curves are shown in Figure 2. No differences were
observed for ethanol concentrations in blood between alcohol
and soy extract+alcohol (Table 2). In both conditions, 10 h
after drug administration, alcohol concentrations in plasma were
deemed undetectable.
Daidzein, Genistein, and Equol
Concentrations
Pharmacokinetic parameters for blood isoflavone concentrations
(daidzein and genistein) over time curves are shown in
Figure 3. Daidzein-concentrations peaked at 6.1 h (±3.2) after
administration and genistein at 7.3 h (±3). The mean Cmax of
daidzein was 1016.5 ng/ml (±303.1) and genistein 1039.0 ng/ml
(±496.9). The concentrations of equol, a metabolite of daidzein,
peaked at 24 h. Its pharmacokinetic parameters could not be
calculated due to a limited number of evaluations (24 h). Multiple
peaks along the plasma concentrations over time suggest an
enterohepatic recirculation of isoflavones.
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DISCUSSION
According to our findings, soy isoflavones neither interact with
alcohol nor induce disulfiram-like effects with respect to alcohol
pharmacokinetics and effects (vital signs and subjective/adverse
effects). A previous study (Penetar et al., 2011) also suggested
that the administration of a purified extract of a kudzu
herbal medication containing isoflavones (mostly puerarin
[19%], followed by daidzin [4%], and daidzein [2%]) did not
increase the intoxicating effects of acute alcohol consumption in
human volunteers (blood alcohol levels, subjective effects, and
psychomotor performance).
We only found slightly significative changes in headache
and, at some time points, facial temperature, and diastolic
blood pressure when alcohol was administered. Such minimal
changes could have been attributed to placebo (nocebo) effects,
nevertheless, as a placebo capsule condition was not included we
cannot substantiate this interpretation.
Our results were similar to a previous pharmacokinetic
study in which the pharmacokinetic parameters for blood
isoflavone concentrations showed double peaks in time-
course plasma, thus supporting enterohepatic recirculation,
characteristic of isoflavone metabolism (Rodríguez-Morató et al.,
2015). We observed that the Tmax for alcohol appeared
between 2.5 and 4 h after administration, the Tmax for
the first peak for daidzein-genistein was between 2 and
4 h, and the maximal concentrations of both isoflavones
were around 6 h. During 0.5–6 h blood alcohol levels
were higher than those recommended for driving, within the
range of the maximal isoflavone concentrations. As isoflavones
show intensive presystemic metabolism concentrations in the
liver they could be elevated enough at 0.5–2 h to inhibit
hepatic metabolic enzymes (Chandrasekharan and Aglin, 2013;
Rodríguez-Morató et al., 2015). We are, however, unaware of the
consequences of alcohol administration regarding the time peak
of isoflavone concentrations.
In contrast to disulfiram, some isoflavones are strong
reversible inhibitors of ALDH2 and mild inhibitors of ALDH1.
In the central nervous system, blocking ALDH2 inhibits
dopamine metabolism by hindering the conversion of DOPAL
to DOPAC, increasing levels of aldehyde DOPAL, and forming
tetrahydropapaveroline (THP) in the ventral tegmental area.
THP inhibits tyrosine hydroxylase (TH) and consequently
decreases dopamine biosynthesis thus blunting the reinforcing
effects of cocaine (Yao et al., 2010). In male mice, daidzein and
genistein decreased cocaine-reinforcing effects, and daidzein, but
not genistein, reduced cue-induced cocaine relapse (Martin et al.,
2013). Alcohol is a substance commonly abused in combination
with cocaine. A number of studies have found that about
60% of individuals with cocaine use disorder have co-occurring
diagnoses of alcohol use disorder (Araos et al., 2017). Taking into
account the pharmacodynamic profile of isoflavones, they could
be used for future clinical trials studying possible treatments for
substance use disorders (alcohol and cocaine,), without requiring
absolute alcohol abstinence as an inclusion requirement.
Our study has some limitations. The sample included a
small number of healthy volunteers and not patients with
substance use disorders. Moreover, only males participated as
isoflavones could present gender-based differences in metabolism
(Soukup et al., 2016). Our research was performed using a
single dose of isoflavones and a standard dose of alcohol
for interaction studies. As the selected isoflavone dose was
within the range of safe menopause symptom therapy, we
are unable to advance results employing higher doses and/or
repeated administrations. Disulfiram-like symptoms also appear
at low-medium doses of alcohol when ALDH1 inhibitors are
administered (Kline et al., 1987; Visapää et al., 2002). We
employed a natural extract with a mixture of isoflavones and
are thus unaware of whether the results could change after a
single dose of each pure isoflavone or metabolite such as equol.
Our study did not include a placebo condition, nevertheless,
the non-significant symptomatic differences reported between
the groups could be explained by placebo/nocebo effects.
Neither were acetaldehyde concentrations analyzed nor any
measure of psychomotor performance performed. The fact
that Japanese and Chinese food contains elevated doses of
isoflavones, and there are no adverse effects when alcohol is
consumed, could support our results demonstrating a possible
isoflavone mechanism of action on ALDH2. We did not,
however, include a measure of the activity of these enzymes,
and our findings do not provide significant evidence about
the effect of soy extract on human aldehyde-dehydrogenase
(or ALDH) isozymes.
CONCLUSION
Substances such as soy isoflavones can be safely administered in
combination with alcohol. They could be a new strategy for the
treatment of substance use disorders without involving the risks
associated with disulfiram.
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